FindTrial
Sign In

A comparative study of Danlong oral liquid in the treatment of acute exacerbation of chronic obstructive pulmonary disease

A comparative study of Danlong oral liquid in the treatment of acute exacerbation of chronic obstructive pulmonary disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200055949
Enrollment
Unknown
Registered
2022-01-28
Start date
2019-12-31
Completion date
Unknown
Last updated
2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AECOPD

Interventions

Danlong oral liquid + conventional western medicine treatment group: None
Conventional western medicine treatment group:None

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of chronic obstructive pulmonary disease; 2. TCM syndrome differentiation is a patient with phlegm heat obstructing lung; 3. Signed a written informed consent to the test.

Exclusion criteria

Exclusion criteria: 1. Patients treated with systemic glucocorticoids; 2. Severe impairment of heart, brain, liver, kidney, hematopoiesis diseases.

Countries

China

Contacts

Public ContactWen Fuqiang

West China Hospital of Sichuan University

wenfuqiang@126.com+86 18980601258

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026